| 12.85 -1.15 (-8.21%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.92 | 1-year : | 19.27 |
| Resists | First : | 14.49 | Second : | 16.49 |
| Pivot price | 14.01  |
|||
| Supports | First : | 11.24 | Second : | 9.35 |
| MAs | MA(5) : | 13.11 |
MA(20) : | 14.34 |
| MA(100) : | 8.95  |
MA(250) : | 226.7 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 37 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 2235 | Low : | 2.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PLRZ ] has closed above bottom band by 35.9%. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.14 - 14.21 | 14.21 - 14.27 |
| Low: | 12.7 - 12.77 | 12.77 - 12.83 |
| Close: | 13.17 - 13.29 | 13.29 - 13.38 |
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Tue, 10 Feb 2026
Biotech Polyrizon lines up $5.8M deal for $19M private jet firm - Stock Titan
Fri, 06 Feb 2026
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Fri, 05 Dec 2025
Polyrizon Ltd. Announces $4.97 Million Securities Offering - TipRanks
Fri, 05 Dec 2025
We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth - Yahoo Finance
Thu, 04 Dec 2025
Polyrizon Surges: A Game-Changer in Progress? - StocksToTrade
Thu, 04 Dec 2025
PLRZ Stock Price and Chart — NASDAQ:PLRZ - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 19.9 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 120 (K) |
| Shares Short P.Month | 176 (K) |
| EPS | -1.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -12.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -12.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|